Focus on Neurology and Psychiatry

This series of bite-sized episodes contains important information you need to navigate the evolving world of Alzheimer’s disease (AD) research. Dr. Marc Agronin and Dr. Richard Isaacson discuss the recent advances in AD and provide practical approaches for prevention, diagnosis, and treatment.

Patients living with MS can experience hidden or invisible symptoms that may not be apparent to others but can affect how they feel and function. In this podcast, Dr. Barry Singer, the Director at the Multiple Sclerosis Center for Innovations in Care, and Rosario, a patient who has been living with MS for 10 years, discuss their clinical and personal experiences with MS, and the impact that MS can have on a patient's QoL.

In the 2-year AFFIRM pivotal trial: Relapsing MS patients received 300 mg TYSABRI every 28 days (n=627) or placebo (n=315). Patients with PPMS, SPMS, and PRMS were excluded.2,3

83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: 17% vs 29%; p<0.001).2,3

Dr. Singer reviews the results of a recent publication from Hersh et al, which describes the effect of TYSABRI® (natalizumab) on various aspects of a patient’s QoL. In the study, 164 patients reported their experience after starting TYSABRI using a standard Quality of Life in Neurological Disorders (Neuro-QoL) assessment of 12 domains, which included anxiety, depression, positive affect and well-being, emotional and behavioral dyscontrol, stigma, cognitive function, sleep disturbance, fatigue, participation and satisfaction with social …

Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.

Ever had a multiple sclerosis (MS) patient who needed to start a DMT? Listen to Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Director of MS Research at Ohio Health, and Kim, a patient who has been living with MS for seven years, share their experiences with the treatment decision process, including benefit-risk considerations, treatment goals, and patient preferences. They talk about the process for starting and continuing treatment with TYSABRI® (natalizumab) and how Biogen Support Services can help.

Please see Important Safety Information, including Boxed Warning for PML, below.

Niemann-Pick disease type C (NPC) is an ultra-rare, inherited, neurodegenerative disease with life-threatening complications. Due to its highly variable onset of neurological symptoms throughout one’s lifespan, recognizing and establishing diagnosis for NPC can be challenging for any clinician.

That’s why Drs. Caroline Hastings and Raymond Y. Wang join Dr. Jennifer Caudle to help address those challenges with a detailed look at this genetic condition, the factors underlying its variable onset and course, and strategies to improve recognition, cross-specialty communications, and time to diagnosis.

Copyright ©2021 Orphazyme A/S. All rights reserved.
NP-USA-1492-v1
ORPHAZYME is a trademark or registered trademark of Orphazyme A/S.

Here to discuss staying ahead of progression in patients with relapsing multiple sclerosis (RMS) is Dr. Timothy William West. Dr. West walks us through pathophysiological changes in progressing RMS patients, a patient case demonstrating why patients may experience increasing disability, and key data on MAYZENT®(siponimod), the first and only oral disease-modifying therapy studied and proven to delay disability progression in a more progressed RMS patient population, including active SPMS.

MAYZENT was evaluated in EXPAND—the largest Phase III study of secondary progressive MS (SPMS) patients to date (N=1651), which included a broad range of patients with moderate-to-advanced disability. Dr. West discusses clinical data from EXPAND including data of up to 5 years from a preplanned interim analysis of the EXPAND open-label extension study.

Behavioral health integration has proven to be an effective solution to improving access to treatment for many mental health conditions… So why is it not more prevalent in the medical community? Joining Dr. Jennifer Caudle to dive into the findings and implications of the joint AMA-RAND Corporation study recently published in the Annals of Internal Medicine are Dr. Kathleen Blake with the AMA and Dr. Peggy Chen from the RAND Corporation.

And, click here to listen to a conversation regarding Behavioral Health Integration and its effect on clinical practice.

Behavioral health integration has proven to be an effective solution to improving access to treatment for many mental health conditions… So why is it not more prevalent in the medical community? Joining Dr. Jennifer Caudle to dive into the findings and implications of the joint AMA-RAND Corporation study recently published in the Annals of Internal Medicine are Dr. Kathleen Blake with the AMA and Dr. Peggy Chen from the RAND Corporation.

And, click here to listen to a conversation regarding Behavioral Health Integration and its effect on clinical practice.

In Chapter 1 of this three-part series that’s designed to help increase the awareness and understanding of the pathophysicology and comorbidities in patients with bipolar disorder or schizophrenia, Dr. Cutler explores the pathophysicology and some comorbidities in patients with bipolar disorder.

This is an informational non-CME program sponsored by Alkermes, Inc. ALKERMES® is a registered trademark of Alkermes, Inc. KEEP THE BODY IN MIND® is a registered service mark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc., under license. ©2020 Alkermes, Inc. All rights reserved.

None of the subjects pictured are actual patients.

UNB-002745

Take a closer look at the pathophysiology of schizophrenia and a range of physical comorbidities with Dr. Cutler in Chapter 2 of this three-part series for the “Keep the Body in Mind” initiative.

This is an informational non-CME program sponsored by Alkermes, Inc. ALKERMES® is a registered trademark of Alkermes, Inc. KEEP THE BODY IN MIND® is a registered service mark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc., under license. ©2020 Alkermes, Inc. All rights reserved.

None of the subjects pictured are actual patients.

UNB-002974